Vanguard Group’s Cellebrite CLBT Stock Holding History

Vanguard Group’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.74M	Sell	96,394 -7,264	-7%	-$130K	﹤0.01%	3605
2025 Q3	$1.92M	Buy	103,658 +11,739	+13%	+$184K	﹤0.01%	3591
2025 Q2	$1.47M	Buy	91,919 +8,712	+10%	+$155K	﹤0.01%	3638
2025 Q1	$1.62M	Buy	83,207 +20,259	+32%	+$426K	﹤0.01%	3559
2024 Q4	$1.39M	Buy	62,948 +8,976	+17%	+$173K	﹤0.01%	3666
2024 Q3	$909K	Buy	53,972 +6,342	+13%	+$94.1K	﹤0.01%	3807
2024 Q2	$569K	Buy	47,630 +17,534	+58%	+$196K	﹤0.01%	3958
2024 Q1	$333K	Hold	30,096	–	–	﹤0.01%	4095
2023 Q4	$261K	Hold	30,096	–	–	﹤0.01%	4181
2023 Q3	$230K	Buy	30,096 +9,934	+49%	+$74.6K	﹤0.01%	4229
2023 Q2	$145K	Hold	20,162	–	–	﹤0.01%	4357
2023 Q1	$123K	Hold	20,162	–	–	﹤0.01%	4381
2022 Q4	$87.9K	Hold	20,162	–	–	﹤0.01%	4405
2022 Q3	$79K	Hold	20,162	–	–	﹤0.01%	4512
2022 Q2	$103K	Hold	20,162	–	–	﹤0.01%	4545
2022 Q1	$129K	Hold	20,162	–	–	﹤0.01%	4579
2021 Q4	$162K	Buy	+20,162	New	+$190K	﹤0.01%	4579

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Vanguard Group's CLBT Position: Q4 2025 in Review

Vanguard Group reduced its Cellebrite (CLBT) stake by 7% in Q4 2025, selling an estimated $130K and leaving 96,394 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #3605.

Vanguard Group first reported a position in CLBT in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.92M in Q3 2025. 209 funds tracked by Wall St. Rank hold CLBT as of Q4 2025.

Vanguard Group held 96,394 shares of Cellebrite worth $1.74M as of Q4 2025.
Vanguard Group sold 7,264 Cellebrite shares in Q4 2025, an estimated $130K.
Cellebrite made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3605 holding.
Vanguard Group first reported a position in Cellebrite in Q4 2021 and has held it in 17 quarters since.
Vanguard Group's Cellebrite position peaked at $1.92M in Q3 2025.
209 funds tracked by Wall St. Rank held Cellebrite as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.